Björn Dahlbäck

From Wikipedia, the free encyclopedia
Björn Dahlbäck (2014)

Björn Dahlbäck (born 1949) is a Swedish physician, medical researcher, and professor of clinical chemistry, specializing in hematology and the molecular mechanisms of blood coagulation.[1] He is perhaps "best known for his groundbreaking discovery of activated protein C (APC) resistance as the most common inherited risk factor of venous thrombosis."[2]

Education and career[]

Dahlbäck graduated with an M.D. from Lund University and then completed his medical internship and residency at Malmö's University Hospital,[2] which is now merged into Skåne University Hospital. In 1981 he received from Lund University his doctorate with dissertation The activation of prothrombin on the platelet surface[3] under the supervision of Johan Stenflo. Dahlbäck was a postdoc at La Jolla's Scripps Research, where his supervisor was Hans J. Müller-Eberhard, and later was a visiting scholar at Oklahoma Medical Research Foundation (OMRF). In 1989 at Lund University, Dahlbäck was appointed a full professor of clinical chemistry, specializing in hematology and cardiac and cardiovascular systems.[2][1] He is also the director of the blood coagulation unit at Malmö General Hospital.[4]

His research was important in showing that APC resistance is caused by a harmful mutation in the F5 gene corresponding to the protein Factor V; the specific mutation was subsequently identified by several groups of researchers and is now called Factor V Leiden.[2] In 2013, Dahlbäck and colleagues identified the F5 gene mutation that causes the phenotype called "east Texas bleeding disorder".[5][2]

Other achievements include the first purification of human FV, the discovery of the complex between protein S and the complement regulator C4BP, identification and cloning of the protein S-binding beta-chain of C4BP, electron microscopy visualization of the spider-like C4BP, sequencing and cloning of protein S, and the creation of Gas6 knockout mice. A noteworthy achievement outside the coagulation field is the identification of apoM, an HDL-associated apolipoprotein, and the discovery that it is the carrier of sphingosine 1-phosphate in the blood.[2]

He has received several honors and awards,[2] including in 1996 the Louis-Jeantet Prize for Medicine[4] and in 2019 H. M. The King's Medal (H.M. Konungens Medalj) of the 12th size from the Royal Court of Sweden.[6] He is a member of the Royal Swedish Academy of Sciences.[7]

In 2000, Academic Press published Hematology: Landmark Papers of the Twentieth Century , which included the 1994 paper Resistance to activated protein C as a basis for venous thrombosis by Peter J. Svensson and Björn Dahlbäck.[8][9]

Selected publications[]

References[]

  1. ^ a b "Björn Dahlbäck, Senior Professor". Lund University.
  2. ^ a b c d e f g "Björn Dahlbäck, Biography". eMedEvents.
  3. ^ Dahlbäck, Björn (1981). The activation of prothrombin on the platelet surface. Malmö.
  4. ^ a b "Professeur Björn Dahlbäck, Laureate de Prix Louis-Jeantet de médecine 1996". Fondation Louis-Jeantet. October 2017. (in French)
  5. ^ Vincent, Lisa M.; Tran, Sinh; Livaja, Ruzica; Bensend, Tracy A.; Milewicz, Dianna M.; Dahlbäck, Björn (2013). "Coagulation factor VA2440G causes east Texas bleeding disorder via TFPIα". Journal of Clinical Investigation. 123 (9): 3777–3787. doi:10.1172/JCI69091. PMC 3754264. PMID 23979162.
  6. ^ "H.M. Konungens Medalj". Sveriges Kungahaus. June 6, 2019.
  7. ^ "Björn Dahlbäck". Kungliga Vetenskaps Akademien.
  8. ^ Lichtman, Marshall A.; Boxer, Laurence A.; Spivak, Jerry L.; Henderson, Edward; Shattil, Sanford J., eds. (27 April 2000). Hematology: Landmark Papers of the Twentieth Century. Academic Press. ISBN 9780124485105.
  9. ^ Svensson, Peter J.; Dahlback, Bjorn (1994). "Resistance to Activated Protein C as a Basis for Venous Thrombosis". New England Journal of Medicine. 330 (8): 517–522. doi:10.1056/NEJM199402243300801. PMID 8302317.
Retrieved from ""